Wela Strategies’s IN8bio INAB Stock Holding History

Wela Strategies’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-618	Closed	-$21.9K	–	51
2024 Q1	$21.9K	Buy	+618	New	+$23.3K	0.01%	49

Other funds holding INAB

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIG

Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Wela Strategies's INAB Position: Q2 2024 in Review

Wela Strategies sold out of IN8bio (INAB) in Q2 2024, closing a stake of 618 shares — an estimated $21.9K sold.

Wela Strategies first reported a position in INAB in Q1 2024 and held it in 1 quarter. The position peaked at $21.9K in Q1 2024. 26 funds tracked by Wall St. Rank hold INAB as of Q2 2024.

Wela Strategies reported no remaining IN8bio position as of Q2 2024 after selling out during the quarter.
Wela Strategies sold 618 IN8bio shares in Q2 2024, an estimated $21.9K.
Wela Strategies first reported a position in IN8bio in Q1 2024 and held it in 1 quarter.
Wela Strategies's IN8bio position peaked at $21.9K in Q1 2024.
26 funds tracked by Wall St. Rank held IN8bio as of Q2 2024.

Based on Wela Strategies's 13F filing for Q2 2024, filed 12 Jul 2024.